WO2007060002A3 - Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung - Google Patents

Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung Download PDF

Info

Publication number
WO2007060002A3
WO2007060002A3 PCT/EP2006/011308 EP2006011308W WO2007060002A3 WO 2007060002 A3 WO2007060002 A3 WO 2007060002A3 EP 2006011308 W EP2006011308 W EP 2006011308W WO 2007060002 A3 WO2007060002 A3 WO 2007060002A3
Authority
WO
WIPO (PCT)
Prior art keywords
profile
therapy
genome
prognosis
recommendation
Prior art date
Application number
PCT/EP2006/011308
Other languages
English (en)
French (fr)
Other versions
WO2007060002A2 (de
Inventor
Ulf Vogt
Burkhard Brandt
Original Assignee
Ulf Vogt
Burkhard Brandt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulf Vogt, Burkhard Brandt filed Critical Ulf Vogt
Priority to EP06829122A priority Critical patent/EP1957671A2/de
Publication of WO2007060002A2 publication Critical patent/WO2007060002A2/de
Publication of WO2007060002A3 publication Critical patent/WO2007060002A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur individualisierten Prognose,- Therapieempfβhlung und/oder -Verfolgung und/oder Nachsorge einer Tumorerkrankung eines Patienten. Derartige Verfahren werden benötigt, um präzise Entscheidungskriterien für eine bestimmte Therapie bzw. die Wiederaufnahme einer Therapie zu erhalten. Erfindungsgemäß wird ein erstes Genomprofil oder Expressionsprofil einer ersten Probe enthaltend Tumorgewebe zum Zeitpunkt der Diagnose des Tumors erfasst wird, das den Genomstatus oder Expressionsstatus einer ersten Vielzahl menschlicher Gene enthält, für den jeweiligen Patienten für eine individuelle Auswahl an menschlichen Genen aus der Vielzahl von erfassten menschlichen Genen der Genomstatus oder Expressionsstatus gespeichert wird, zu einem späteren Zeitpunkt für die Gene der individuellen Auswahl ein weiteres Genomprofil oder Expressionsprofil einer zweiten Probe, enthaltend Lymphknotengewebe, Knochenmark und/oder eine Körperf lüssigkeit, erfasst und mit dem ersten Genomprofil oder Expressionsprofil verglichen, und aufgrund dieses Vergleichs eine Therapieempfehlung, eine Prognosebeurteilung oder eine Therapiebeurteilung durchgeführt.
PCT/EP2006/011308 2005-11-25 2006-11-24 Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung WO2007060002A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06829122A EP1957671A2 (de) 2005-11-25 2006-11-24 Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200510056365 DE102005056365A1 (de) 2005-11-25 2005-11-25 Verfahren zur individualisierten Prognose, Therapieempfehlung und/oder -verfolgung und/oder Nachsorge einer Tumorerkrankung
DE102005056365.1 2005-11-25

Publications (2)

Publication Number Publication Date
WO2007060002A2 WO2007060002A2 (de) 2007-05-31
WO2007060002A3 true WO2007060002A3 (de) 2007-11-15

Family

ID=38037670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/011308 WO2007060002A2 (de) 2005-11-25 2006-11-24 Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung

Country Status (3)

Country Link
EP (1) EP1957671A2 (de)
DE (1) DE102005056365A1 (de)
WO (1) WO2007060002A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007051757A1 (de) 2007-10-30 2009-05-07 Ecker, Felix, Prof. Dr. Verfahren zur automatischen Herstellung von patientenindividuell dosierten pharmazeutischen Zubereitungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194701A1 (en) * 2000-11-20 2003-10-16 Golub Todd R. Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
US20020155480A1 (en) * 2001-01-31 2002-10-24 Golub Todd R. Brain tumor diagnosis and outcome prediction
AU2002354941A1 (en) * 2001-07-17 2003-03-03 Dana-Farber Cancer Institute, Inc. Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia
US20050074793A1 (en) * 2003-04-04 2005-04-07 Wilson Keith E. Metastatic colorectal cancer signatures

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BOSMA A J ET AL: "Detection of Ciculating Breast Tumor Cells by Differential Expression of Marker Genes", CLINICAL CANCER RESEARCH, THE ASSOCIATION, DENVILLE, NJ, US, vol. 8, no. 6, June 2002 (2002-06-01), pages 1871 - 1877, XP002989678, ISSN: 1078-0432 *
KODA MARIUSZ ET AL: "Expression of ERalpha, ERbeta and Ki-67 in primary tumors and lymph node metastases in breast cancer.", ONCOLOGY REPORTS APR 2004, vol. 11, no. 4, April 2004 (2004-04-01), pages 753 - 759, XP002444940, ISSN: 1021-335X *
MONTEL V ET AL: "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model", AMERICAN JOURNAL OF PATHOLOGY 2005 UNITED STATES, vol. 166, no. 5, 2005, pages 1565 - 1579, XP002444939, ISSN: 0002-9440 *
PANTEL ET AL: "Detection and molecular characterisation of disseminated tumour cells: Implications for anti-cancer therapy", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 1, 25 September 2005 (2005-09-25), pages 53 - 64, XP005060826, ISSN: 0304-419X *
SUELLEN TOTH-FEJEL ET AL: "DNA Fingerprints Provide a Patient-Specific Breast Cancer Marker", ANNALS OF SURGICAL ONCOLOGY, SPRINGER-VERLAG, NE, vol. 11, no. 6, 1 June 2004 (2004-06-01), pages 560 - 567, XP019369514, ISSN: 1534-4681 *
TSUTSUI SHINICHI ET AL: "Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer", BREAST CANCER, JAPANESE BREAST CANCER SOCIETY, TOKYO, JP, vol. 9, no. 2, April 2002 (2002-04-01), pages 111 - 117, XP009087503, ISSN: 1340-6868 *
WEIGELT B ET AL: "Gene expression profiles of primary breast tumors maintained in distant metastases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 23 DEC 2003 UNITED STATES, vol. 100, no. 26, 23 December 2003 (2003-12-23), pages 15901 - 15905, XP002444938, ISSN: 0027-8424 *
ZIEGLSCHMID V ET AL: "DETECTION OF DISSEMINATED TUMOR CELLS IN PERIPHERAL BLOOD", CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, CRC PRESS, BACA RATON, FL, US, vol. 42, no. 2, 2005, pages 155 - 196, XP008066221, ISSN: 1040-8363 *

Also Published As

Publication number Publication date
EP1957671A2 (de) 2008-08-20
WO2007060002A2 (de) 2007-05-31
DE102005056365A1 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2006048881A3 (en) A method and system for diagnosis of cardiac diseases utilizing neural networks
WO2008148115A8 (en) Methods, systems, and kits for evaluating multiple sclerosis
WO2005029067A3 (en) Method of diagnosing breast cancer
HK1063423A1 (en) Methods to diagnose treat and prevent bone loss
EP1541193A4 (de) MEDIZINISCHES BEHANDLUNGSSYSTEM UNTER VERWENDUNG EINES BIOLOGISCHEN REGULIERUNGSFUNKTIONSVERûNDERERS, SCHRITTMACHERSYSTEM AUF BASIS DES MEDIZINISCHEN BEHANDLUNGSSYSTEMS, BLUTDRUCKREGULIERSYSTEM UND SYSTEM ZUR BEHANDLUNG VON HERZKRANKHEITEN
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2004044556A3 (en) Diagnosis of sepsis or sirs using biomarker profiles
WO2006058306A3 (en) Medical hyperspectral imaging for evaluation of tissue and tumor
WO2002053028A8 (en) Electrical impedance method and apparatus for detecting and diagnosing diseases
MX2009003562A (es) Ensayo elisa para la deteccion de vegf.
WO2006084272A3 (en) Methods of predicting chemotherapy responsiveness in breast cancer patients
EP2503338A3 (de) CD73 als Biomarker zur Überwachung der Entwicklung von Krankheiten und zum Testen der Wirksamkeit von Therapien
WO2005118875A3 (en) Diagnosing or predicting the course of breast cancer
EP2365335A3 (de) Diagnoseverfahren
Tolkachov et al. Loss of the hematopoietic stem cell factor GATA2 in the osteogenic lineage impairs trabecularization and mechanical strength of bone
WO2007124820A3 (de) Verfahren zur in-vitro überwachung postoperativer veränderungen nach lebertransplantation
WO2016146254A8 (en) Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia
WO2004050907A3 (en) Method for determing predisposition to manifestation of immune system related diseases
WO2007060002A3 (de) Verfahren zur individualisierten prognose, therapieempfehlung und/oder -verfolgung und/oder nachsorge einer tumorerkrankung
EP1695092B8 (de) Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie
CN105200137A (zh) Cers2 基因及其表达产物作为骨质疏松症的诊治靶标
Gallagher-Ross Predictors of posttraumatic growth in breast cancer survivors: An analysis of hardiness, attachment, and cognitive appraisal
WO2009084898A3 (en) System and method for analysing brain wave
MY147511A (en) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3-marker
WO2006136474A3 (de) Verfahren zur ermittlung eines biomarkers zur kennzeichnung eines spezifischen biologischen zustands eines organismus aus mindestens einem datensatz

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006829122

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006829122

Country of ref document: EP